Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Promoting excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
10:10 - 10:50 - Bernard Gersh (Rochester,USA)
Dr. Gersh is Professor of Medicine at the Mayo Clinic College of Medicine having received his undergraduate degree at the University of Cape Town and obtaining a D.Phil at Oxford University. He also has an Honorary PhD from the University of Coimbra, Portugal. He has published approximately 880 manuscripts, 140 book chapters, and has edited 15 books. He has served on multiple editorial boards and is currently Deputy Editor of the European Heart Journal. Prior awards include the Silver Medal of the European Society of Cardiology, the James B. Herrick Award, the Distinguished Achievement Award of the American Heart Association, Master of the American College of Cardiology, and the Hatter Award for the Advancement of Cardiovascular Science from the University College London and the University of Cape Town. Dr. Gersh is the 2015 recipient of the Mayo Clinic Distinguished Alumni Award.
15:40 to 16:20 - Alain Cribier (Rouen, FR)
Prof. Alain Cribier, MD, has been for 20 years Chief of Cardiology at the University Hospital Charles Nicolle of Rouen, France. He became widely recognized for having developed new interventional technologies for the treatment of valvular heart diseases: Balloon Aortic Valvuloplasty in 1985, Mitral Commissurotomy in 1994, and after 15 years of research the Transcatheter Implantation of Aortic Valves (TAVI), performing the first world case in Rouen in 2002. This last breakthrough technology which is now widely used in the world with more than 300 000 patients treated and an explosive growth will have a durable impact on the pattern of medical practice. Prof Cribier has received a number of prestigious scientific distinctions and awards for his pioneering work. He has published more than 600 indexed articles in the fields of interventional cardiology, valve disease and innovative technologies.
Epidemiology and prevention of cardiovascular disease: quo vadis?
Guy De Backer (Ghent,BE)
Guy De Backer graduated in 1968 as medical doctor at the University of Ghent, Belgium. He holds special degrees in cardiology and in cardiac rehabilitation and he was awarded with an additional degree in public health. In 1979 he was awarded with a PhD in epidemiology at Ghent University with a dissertation based on results from the Belgian Heart Disease Prevention Project, part of the WHO European Collaborative Project that was coordinated by Professor Geoffrey Rose. From 1988 onwards he was professor of medicine at Ghent University chairing the Department of Public Health from 1989-2009. At the University Hospital in Ghent he has been chairing the Cardiac Rehabilitation centre from 1983-2009 and the Department of Cardiology from 2007-2009. At the ESC level he chaired the Working group on epidemiology and prevention in 1990-1992 and from 1994 until now he has been involved in numerous guidelines on CVD prevention, dyslipidaemia and arterial hypertension. Guy De Backer is a member and the past-chairman (1996-2009) of the Superior Health Council of Belgium and a member and the past-president (2007-2010) of the Royal Academy of Medicine of Belgium.
Renaissance of signalling modules: The role of STAT3 in the cardiac pathophysiology
Denise Hilfiker-Kleiner (Hannover, DE)
Professor Denise Hilfiker-Kleiner is dean of research of the Hannover Medical School (MHH) and leads the Department of Molecular Cardiology within the Department of Cardiology and Angiology of the MHH. She has a longstanding experience in analysing signalling pathways in cardiac cells relevant for cardiac physiological and pathophysiological processes as well as for endogenous regeneration abilities of the heart especially after pregnancy or treatment with cardiotoxic agents. She is member of the Commission of Experimental Research of the German Cardiac Society and member of a commission which counsels the German Council of Science and Humanities of the German Federal Government and the State. She is a fellow of the ESC and past chair of the ESC Working Group on Myocardial Function. She is a founding member of the study group on PPCM and of the translational research group of the Heart Failure Association (HFA) of the ESC. She has been associated partner of a Leducq Foundation Transatlantic Network of Excellence in cardiovascular sciences, where she was the main manager and is a core PI of the REBIRTH Excellence Cluster at the MHH. She is the lead scientist and organiser of the multicentre clinical trial on the efficacy of bromocriptine in PPCM funded by the German Federal Ministry of Education and Research (BMBF).
From balloon to bioresorbable scaffold: a 30-year journey in coronary intervention
Jean Fajadet (Toulouse, FR)
Graduated from the University Hospital of Toulouse in 1984, Dr Fajadet has more than 30 years of experience in the field of interventional cardiology.He is currently Co-director of the Interventional Cardiovascular Group at Clinique Pasteur which is the leading center in France.Dr Fajadet has been involved as principal investigator or co-investigator in several major clinical trials involving new technologies and devices in the field of interventional cardiology. He has written and co-authored many articles published in peer-reviewed journals such as EuroIntervention, JACC, Circulation, European Heart Journal.He is also fully dedicated to Education which is a paramount axe of his carreer. This includes the fellowship programme at Clinique Pasteur and active participation in many worldwide educational meetings (Europe, US, Asia and South America) throughout the year.Dr Fajadet is one of the co-founder and course director of the EuroPCR congress (the largest interventional cardiology course in the world). He is also course director of GulfPCR and PCR London Valves and course co-director of AsiaPCR.Dr Fajadet is Past-President of EAPCI (European Association of Percutaneous Cardiovascular Interventions, a registered branch of the ESC) and Fellow of the European Society of Cardiology.
Aortic stenosis - A "simple" heart defect with ongoing diagnostic and therapeutic challenges
Helmut Baumgartner (Muenster, DE)
Helmut Baumgartner is Professor of Cardiology and Congenital Heart Disease at the University of Muenster and Director of the Division of Adult Congenital and Valvular Heart Disease at the University Hospital Muenster, Germany. He graduated from University in Vienna, Austria and trained in cardiology at the Hospital Barmherzige Schwestern, Linz, Austria (Professor Peter Kuehn) and at Cedars Sinai Medical Center, Los Angeles, USA (Professor Gerald Maurer) with later clinical and academic posts at the University of Vienna and Vienna General Hospital.His research activities focus on noninvasive assessment, natural history, outcome after repair, predictors of outcome with impact on management and catheter interventional treatment of adult congenital and valvular heart disease. This research had impact on the current practice guidelines for the management of valvular and adult congenital heart disease, such as the assessment of aortic stenosis and prosthetic heart valves, and the management of aortic stenosis, mitral regurgitation, atrial septal defect and ventricular septal defect.